• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by 908 Devices Inc. (Amendment)

    2/9/24 5:34:50 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials
    Get the next $MASS alert in real time by email
    SC 13G/A 1 arch-sch13g_18793.htm ARCH VENTURE FUND VII, L.P. - 908 DEVICES INC. -- SCH 13G/A(#3)

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

      (Amendment No. 3)*

     

     

     

     

    908 Devices Inc.

    (Name of Issuer)

       

    Common Stock par value $0.001 per share

     

    (Title of Class of Securities)

      

    65443P102

     

    (CUSIP Number)

      

    December 31, 2023

     

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐   Rule 13d-1(b)

    ☐   Rule 13d-1(c)

    ☒   Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

    CUSIP No.  65443P102

    13G Page 2 of 11 Pages    

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Fund VII, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    5,725,045

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    5,725,045

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,725,045

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    17.7%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

     

    CUSIP No.  65443P102

    13G Page 3 of 11 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners VII, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    5,725,045

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    5,725,045

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,725,045

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    17.7%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

    CUSIP No.  65443P102

    13G Page 4 of 11 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners VII, LLC

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    5,725,045

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    5,725,045

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,725,045

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    17.7%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    OO

     

       

     
     

    CUSIP No.  65443P102

    13G Page 5 of 11 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Keith Crandell

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    31,397

     

      6  

    SHARED VOTING POWER

     

    5,725,045

     

      7  

    SOLE DISPOSITIVE POWER

     

    31,397

     

      8  

    SHARED DISPOSITIVE POWER

     

    5,725,045

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,756,442

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    17.8%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  65443P102

    13G Page 6 of 11 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Clinton Bybee

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    5,725,045

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    5,725,045

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,725,045

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    17.7%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  65443P102

    13G Page 7 of 11 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Robert Nelsen

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    5,725,045

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    5,725,045

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,725,045

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    17.7%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  65443P102

    13G Page 8 of 11 Pages    

     

     

    Item 1(a). Name of Issuer

     

    908 Devices Inc. (the “Issuer”).

     

     

    Item 1(b). Address of Issuer's Principal Executive Offices

     

    645 Summer Street, Boston, MA 02210

     

     

    Item 2(a). Name of Person Filing

     

    ARCH Venture Fund VII, L.P. (“ARCH Venture Fund VII”); ARCH Venture Partners VII, L.P. (“AVP VII LP”); ARCH Venture Partners VII, LLC (“AVP VII LLC”) (collectively, the “Reporting Entities” and individually, each a “Reporting Entity”); and Keith Crandell (“Crandell”), Robert Nelsen (“Nelsen”) and Clinton Bybee (“Bybee”) (collectively, the “Managing Directors” and individually, each a “Managing Director”). The Reporting Entities and the Managing Directors collectively are referred to as the “Reporting Persons”.

     

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    8755 W. Higgins Road, Suite 1025, Chicago, IL 60631

     

     

    Item 2(c). Citizenship

     

    ARCH Venture Fund VII and AVP VII LP are limited partnerships organized under the laws of the State of Delaware. AVP VII LLC is a limited liability companies organized under the laws of the State of Delaware. Each Managing Director is a US citizen.

     

     

    Item 2(d). Title of Class of Securities

     

    Common stock, par value $0.001 per share.

     

     

    Item 2(e). CUSIP Number

     

    65443P102

     

      

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    Not Applicable.

     

     
     

    CUSIP No.  65443P102

    13G Page 9 of 11 Pages    

     

    Item 4. Ownership

     

    (a)

    Amount beneficially owned:

     

    ARCH Venture Fund VII is the record owner of 5,725,045 shares of Common Stock (the “Record Shares”) as of December 31, 2023. AVP VII LP, as the sole general partner of ARCH Venture Fund VII, may be deemed to beneficially own the Record Shares. AVP VII LLC, as the sole general partner of AVP VII, may be deemed to beneficially own the Record Shares. As managing directors of AVP VII LLC, each Managing Director may also be deemed to share the power to direct the disposition and vote of the Record Shares. In addition, as of December 31, 2023, Crandell is a holder of vested options to purchase 31,397 shares of Common Stock (the “Vested Option Shares”).

     

    (b)

    Percent of class:

     

    See line 11 of the cover sheets. The percentages set forth on the cover sheet for each Reporting Person (other than Crandell) is based upon 32,379,113 shares of common stock outstanding as of November 2, 2023, as reported on the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 7, 2023. For Crandell, the Vested Option Shares were included in the number of shares of Common stock outstanding.

       
    (c) Number of shares as to which such person has:

      (i)

    Sole power to vote or to direct the vote:

     

    See line 5 of the cover sheets.

         
      (ii)

    Shared power to vote or to direct the vote:

     

    See line 6 of the cover sheets.

         
      (iii)

    Sole power to dispose or to direct the disposition:

     

    See line 7 of the cover sheets.

         
      (iv)

    Shared power to dispose or to direct the disposition:

     

    See line 8 of the cover sheets.

         

    Each Reporting Person disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record.

     

    Item 5. Ownership of Five Percent or Less of a Class

    Not Applicable.

     

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

     

    Not Applicable.

     

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

     

    Item 10. Certification

     

    Not Applicable.

      

     
     

    CUSIP No.  65443P102

    13G Page 10 of 11 Pages    

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:    February 9, 2024

    ARCH VENTURE FUND VII, L.P.

     

    By:       ARCH Venture Partners VII, L.P.

    its General Partner

     

    By:       ARCH Venture Partners VII, LLC

    its General Partner

     

    By:                    *               

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS VII, L.P.

     

    By:       ARCH Venture Partners VII, LLC

    its General Partner

     

    By:                           *                    

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS VII, LLC

     

    By:                           *                                

    Keith Crandell

    Managing Director

     

     

                                      *                                 

    Keith Crandell

     

     

                                      *                                 

    Robert Nelsen

     

     

                                      *                                 

    Clinton Bybee

     

     

     

     

     

     

     

     

    * By:   /s/ Mark McDonnell                  

    Mark McDonnell as

    Attorney-in-Fact

     

    *         This Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney included as Exhibit 2 to the Form 13G relating to the beneficial ownership of shares of 908 Devices Inc. by the Reporting Persons filed with the Securities and Exchange Commission on February 4, 2021, and incorporated herein in its entirety by reference.

     

     
     

    CUSIP No.  65443P102

    13G Page 11 of 11 Pages    

     

     

    Exhibit 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of 908 Devices Inc.

     

    This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

     

     

    Dated:    February 9, 2024

    ARCH VENTURE FUND VII, L.P.

     

    By:       ARCH Venture Partners VII, L.P.

    its General Partner

     

    By:       ARCH Venture Partners VII, LLC

    its General Partner

     

    By:                    *              

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS VII, L.P.

     

    By:       ARCH Venture Partners VII, LLC

    its General Partner

     

    By:                        *                       

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS VII, LLC

     

    By:                           *                             

    Keith Crandell

    Managing Director

     

     

                                      *                                 

    Keith Crandell

     

     

                                      *                                 

    Robert Nelsen

     

     

                                      *                                 

    Clinton Bybee

     

     

     

     

     

     

     

    * By:   /s/ Mark McDonnell                  

    Mark McDonnell as

    Attorney-in-Fact

     

     

    *         This Agreement was executed by Mark McDonnell pursuant to Powers of Attorney included as Exhibit 2 to the Form 13G relating to the beneficial ownership of shares of 908 Devices Inc. by the Reporting Persons filed with the Securities and Exchange Commission on February 4, 2021, and incorporated herein in its entirety by reference.

     

     
    Get the next $MASS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MASS

    DatePrice TargetRatingAnalyst
    8/5/2025$12.00Market Perform → Outperform
    Leerink Partners
    11/13/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    2/7/2023$14.00Overweight
    Stephens
    3/8/2022$40.00 → $30.00Outperform
    SVB Leerink
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $MASS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Knopp Kevin J. bought $66,596 worth of shares (15,000 units at $4.44), increasing direct ownership by 2% to 722,733 units (SEC Form 4)

    4 - 908 Devices Inc. (0001555279) (Issuer)

    5/19/25 4:37:42 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    Director Spoto Mark bought $42,850 worth of shares (10,000 units at $4.29), increasing direct ownership by 19% to 62,971 units (SEC Form 4)

    4 - 908 Devices Inc. (0001555279) (Issuer)

    5/15/25 4:52:08 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    President and CEO Knopp Kevin J. bought $64,788 worth of shares (15,000 units at $4.32), increasing direct ownership by 2% to 707,733 units (SEC Form 4)

    4 - 908 Devices Inc. (0001555279) (Issuer)

    5/14/25 4:28:02 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    $MASS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    908 Devices upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded 908 Devices from Market Perform to Outperform and set a new price target of $12.00

    8/5/25 1:46:38 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    908 Devices downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded 908 Devices from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously

    11/13/24 8:05:47 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    Stephens initiated coverage on 908 Devices with a new price target

    Stephens initiated coverage of 908 Devices with a rating of Overweight and set a new price target of $14.00

    2/7/23 6:37:28 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    $MASS
    SEC Filings

    View All

    SEC Form 144 filed by 908 Devices Inc.

    144 - 908 Devices Inc. (0001555279) (Subject)

    5/28/26 4:34:42 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    SEC Form SD filed by 908 Devices Inc.

    SD - 908 Devices Inc. (0001555279) (Filer)

    5/28/26 7:30:14 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by 908 Devices Inc.

    SCHEDULE 13G/A - 908 Devices Inc. (0001555279) (Subject)

    5/15/26 4:05:03 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    $MASS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $MASS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that on June 1, 2026, the Compensation Committee of its Board of Directors granted options to four new non-executive employees to purchase an aggregate of 179,912 shares of 908 Devices' common stock. The options were granted as a material inducement to employment with 908 Devices Inc. in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the 908 Devices Inc. 2026 Inducement Plan (the "Plan"). The inducement stock option has an exercise price of $8.63 per share, which is equal to the cl

    6/2/26 4:30:00 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    908 Devices to Present at the 16th Annual East Coast IDEAS Investor Conference

    908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 16th Annual East Coast IDEAS Conference on Wednesday, June 10, 2026. The Company presentation is scheduled to begin at 8:35 a.m. Eastern Time. The presentation is webcast and can be accessed through the conference host's main website: https://www.threepartadvisors.com/east-coast and in the investor relations section of the company website at: www.908devices.com. About 908 Devices 908 Devices is

    5/28/26 7:00:00 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook

    Revenue increased 14% compared to prior year, growth in both Mass Spec and FTIR Acquired NIRLAB AG, expanding narcotics identification capabilities 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026. "We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion," said Kevin J. Knopp, CEO and Co-founder. "We are also excited to announce the acquisition of NIRLAB AG, a strategic transaction that broadens our reach into the lower-cost, widely-deployable segm

    5/6/26 7:30:00 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    Large owner Awm Investment Company, Inc. sold $1,612,091 worth of 908 DEVICES (186,942 units at $8.62) (SEC Form 4)

    4 - 908 Devices Inc. (0001555279) (Issuer)

    5/29/26 4:48:52 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    Director Brown Christopher D. sold $270,000 worth of shares (30,000 units at $9.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 895,559 units (SEC Form 4)

    4 - 908 Devices Inc. (0001555279) (Issuer)

    5/29/26 4:15:19 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    Chief Financial Officer Griffith Joseph H. Iv sold $62,668 worth of shares (6,940 units at $9.03) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 132,956 units (SEC Form 4)

    4 - 908 Devices Inc. (0001555279) (Issuer)

    5/29/26 4:15:19 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    $MASS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

    SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

    11/14/24 5:11:18 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

    SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

    11/14/24 4:25:10 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

    SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

    7/8/24 4:32:41 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    $MASS
    Leadership Updates

    Live Leadership Updates

    View All

    908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the appointment of Kola Otitoju as its Chief Business & Strategy Officer, a newly created executive position. Mr. Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as 908 Devices expands its market presence across public health, safety, and defense-tech applications. Mr. Otitoju brings over 25 years of proven executive leadership in strategy, business development, and P&L management across the medical technology, life sciences, and industrial sectors. Most recently, he served as Senior Vice President of

    4/21/26 5:00:00 PM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    908 Devices Appoints Dr. Brandi Vann, former U.S. Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Dr. Brandi Vann to serve on its Board of Directors. During more than 15 years at the U.S. Department of Defense (DoD), Dr. Vann held several leadership positions overseeing nuclear, chemical, and biological defense programs. The company also announces that Jeff George, a veteran biopharma leader, has stepped down from its Board of Directors due to the company's strategic refocus on public health, safety and defense tech. These changes are effective immediately. Previously, Dr. Vann was Performing the Duties of the Assistant Secretary of Defense for Nuclear, Ch

    8/4/25 7:00:00 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    908 Devices Appoints Christopher D. Brown to its Board of Directors

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

    6/16/25 8:00:00 AM ET
    $AAPL
    $MASS
    $RGEN
    Computer Manufacturing
    Technology
    Industrial Machinery/Components
    Industrials

    $MASS
    Financials

    Live finance-specific insights

    View All

    908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook

    Revenue increased 14% compared to prior year, growth in both Mass Spec and FTIR Acquired NIRLAB AG, expanding narcotics identification capabilities 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026. "We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion," said Kevin J. Knopp, CEO and Co-founder. "We are also excited to announce the acquisition of NIRLAB AG, a strategic transaction that broadens our reach into the lower-cost, widely-deployable segm

    5/6/26 7:30:00 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    908 Devices Acquires NIRLAB AG, Expanding Its Narcotics Detection Portfolio

    Strategic acquisition adds integrated hardware and cloud subscription platform powered by NIR spectroscopy 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has completed the acquisition of NIRLAB AG, a privately held company based in Lausanne, Switzerland. The company delivers AI-powered, cloud-connected near-infrared (NIR) spectroscopy to perform handheld chemical analysis of narcotics in seconds. This acquisition expands 908 Devices' analytical portfolio and strengthens its leadership in narcotics detection with NIRLAB's solution for fast, high-volume screening for everyday law enforcement patrol. The NIRLAB handhel

    5/6/26 7:00:00 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials

    908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026

    908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the first quarter 2026 before market open on Wednesday, May 6, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld dev

    5/1/26 8:30:00 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials